ITRMF · Iterum Therapeutics plc · Debt
$0.03
+0.01 (+34.78%)
At close · Jul 21
Return incl. dividend (before tax)
Q3 2025 earnings call transcript
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“This condition raises substantial doubt about the Company's ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 14, 2025
Market Cap
$446
Shares
44.66M
Volume · Jul 21
18.8K
Avg daily vol (3M)
99.9K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2025-09-30 | USD 0 | 10-Q filed 2025-11-14 |
| Long-term debt, including current maturities | 2025-09-30 | USD 20,045,000 | 10-Q filed 2025-11-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.